IMMUNOBIOGRAM PHARMACOECONOMIC MODEL IN KIDNEY TRANSPLANTATION
Graft failure in Kidney Transplant is associated with high direct costs and a decrease in patient’s quality of life due to the high possibility of ending up in dialysis or retransplantation. New interventions are needed to improve immunosuppressive drugs adjustment an an individualized way to prevent graft failure, reduce related adverse events, and decrease the associated costs.
Patients with HIGH RISK of graft rejection
For stable, low risk patients, the use of the IMBG would entail an expected reduction in the adverse events rate with savings of € 1,419 per patient in 5 years, and a 97,7% saving probability.
Patients with LOW RISK of graft rejection
Therefore, the routinely use of the Immunobiogram in patients one year after their kidney transplant may have considerable savings for the Spanish NHS.